Journal article
The accuracy and precision of the KIM motion monitoring system used in the multi-institutional TROG 15.01 Stereotactic Prostate Ablative Radiotherapy with KIM (SPARK) trial
Emily A Hewson, Doan Trang Nguyen, Ricky O'Brien, Jung-Ha Kim, Tim Montanaro, Trevor Moodie, Peter B Greer, Nicholas Hardcastle, Thomas Eade, Andrew Kneebone, George Hruby, Amy J Hayden, Sandra Turner, Shankar Siva, Keen-Hun Tai, Perry Hunter, Joshua Sams, Per Rugaard Poulsen, Jeremy T Booth, Jarad Martin Show all
MEDICAL PHYSICS | WILEY | Published : 2019
DOI: 10.1002/mp.13784]
Abstract
PURPOSE: Kilovoltage intrafraction monitoring (KIM) allows for real-time image guidance for tracking tumor motion in six-degrees-of-freedom (6DoF) on a standard linear accelerator. This study assessed the geometric accuracy and precision of KIM used to guide patient treatments in the TROG 15.01 multi-institutional Stereotactic Prostate Ablative Radiotherapy with KIM trial and investigated factors affecting accuracy and precision. METHODS: Fractions from 44 patients with prostate cancer treated using KIM-guided SBRT were analyzed across four institutions, on two different linear accelerator models and two different beam models (6 MV and 10 MV FFF). The geometric accuracy and precision of KIM ..
View full abstractGrants
Awarded by Prostate Cancer Foundation of Australia
Awarded by Cancer Australia
Awarded by Cancer Australia Grant (Priority-Driven Collaborative Cancer Research Scheme)
Funding Acknowledgements
The authors would like to thank the Department of Radiation Oncology Calvary Mater Newcastle, the Department of Radiation Oncology Northern Sydney Cancer Centre, Crown Princess Mary Cancer Centre, Peter MacCallum Cancer Centre and the Liverpool Cancer Therapy Centre Radiation Oncology Unit for their clinical support for this study. The authors would also like to acknowledge Helen Ball, Julia Johnson and Shona Silvester for their constant support at the ACRF Image X Institute. The authors also thank the TROG SPARK trial coordinators for their management of this trial. Finally, we would like to thank the patients who participated in this clinical trial and trusted us with their care. This work was funded by co-funded by the Prostate Cancer Foundation of Australia and Cancer Australia (APP1081534). This work is also supported by a Cancer Australia Grant (Priority-Driven Collaborative Cancer Research Scheme - APP1085360). D.T. Nguyen is funded by NHMRC and Cancer Institute of New South Wales Early Career Fellowship. P.J. Keall acknowledges funding from an NHMRC Senior Principal Research fellowship.